Interference with the renin-angiotensin system (RAS): Classical inhibitors and novel approaches

Katrina M Mirabito Colafella, Estrellita Uijl, Jan Danser

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

The renin–angiotensin system is one of the key long-term regulators of blood pressure and has been a mainstay for the treatment of cardiovascular and renal diseases for the last 30 years. In recent years, new components of the renin–angiotensin system have been discovered beyond the classical pathway that have led to the development of novel therapies targeting this system. Moreover, dual inhibitors which block the renin–angiotensin system and other systems involved in the regulation of blood pressure may provide superior treatment for cardiovascular and renal diseases.
Original languageEnglish
Title of host publicationReference Module in Biomedical Sciences
Subtitle of host publicationEncyclopedia of Endocrine Diseases
PublisherElsevier
Number of pages8
Edition2nd
ISBN (Print)9780128121993
DOIs
Publication statusPublished - Oct 2018

Keywords

  • angiotensin receptor blocker neprilysin inhibitor (ARNI)
  • angiotensin II type 1 receptor
  • angiotensin II type 2 receptor
  • angiotensin receptor blockers
  • angiotensin-converting enzyme inhibitors
  • blood pressure
  • cardiovascular disease
  • compound 21
  • diabetes
  • kidney disease
  • Mas receptor
  • neprilysin

Cite this

Mirabito Colafella, K. M., Uijl, E., & Danser, J. (2018). Interference with the renin-angiotensin system (RAS): Classical inhibitors and novel approaches. In Reference Module in Biomedical Sciences: Encyclopedia of Endocrine Diseases (2nd ed.). Elsevier. https://doi.org/10.1016/B978-0-12-801238-3.65341-2